gout: A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
119 |
4. Check minimum number of eventsNone |
119 |
5. Include endpointsNone |
119 |
6. Filter based on genotype QC (FinnGen only) |
117 |
Control definitions (FinnGen only)
- Control exclude
- GOUT
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M10
- Name in latin
- Alia arthritis urica secundaria
Other secondary gout
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 964 | 358 | 599 |
| Only index persons | 824 | 302 | 522 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 71.27 | 76.27 | 68.30 |
| Only index persons | 70.71 | 75.58 | 67.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 117 | 37 | 80 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.04 |
| Median age at first event (years) | 67.88 | 68.14 | 67.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 119
- Matched controls
- 1190
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M10.4
ICD-10 Finland
Other secondary gout
+∞
171.8
119
*
M10.9
ICD-10 Finland
Gout, unspecified
47.2
85.3
56
22
M04AA01
ATC
allopurinol; systemic
24.9
73.2
83
101
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
12.8
33.1
38
42
M10.0
ICD-10 Finland
Idiopathic gout
58.7
32.2
37
9
C03CA01
ATC
furosemide; systemic
7.0
22.5
87
334
B01AA03
ATC
warfarin; systemic
5.6
19.5
60
184
A46
ICD-10 Finland
Erysipelas
5.9
18.3
44
108
212
Kela drug reimbursment
Gout
+∞
18.2
17
*
I50.9
ICD-10 Finland
Heart failure, unspecified
5.1
17.2
55
171
I50.0
ICD-10 Finland
Congestive heart failure
6.0
17.1
38
86
M10
ICD-10 Finland
Gout
17.1
17.0
27
20
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
31.5
16.2
21
8
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
37.2
15.3
19
6
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.3
14.1
60
227
C03DA01
ATC
spironolactone; oral
4.9
13.7
39
108
N18.8
ICD-10 Finland
Other chronic renal failure
19.7
13.5
20
12
I48
ICD-10 Finland
Atrial fibrillation and flutter
4.2
13.5
59
226
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
5.5
13.4
31
72
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.3
13.1
49
167
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.3
12.6
44
142
M13.9
ICD-10 Finland
Arthritis, unspecified
6.7
12.5
22
39
K78
ICPC
Atrial fibrillation/flutter
5.6
12.4
27
59
H02AB06
ATC
prednisolone; systemic
4.3
12.3
85
439
A11CC03
ATC
alfacalcidol; systemic
19.0
12.1
18
11
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.8
12.1
25
52
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.5
11.9
37
109
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.8
11.9
32
84
I50.1
ICD-10 Finland
Left ventricular failure
6.1
11.8
23
45
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.2
11.6
87
469
205
Kela drug reimbursment
Chronic hypertension
3.7
11.5
60
254
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
5.2
11.3
27
64
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.2
11.2
38
119
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.1
10.9
39
127
B03XA02
ATC
darbepoetin alfa; parenteral
18.2
10.7
16
10
A10BH05
ATC
linagliptin; oral
5.5
10.2
22
47
WX002
NOMESCO Finland
Sedation and analgesia
3.8
10.1
41
145
D64.9
ICD-10 Finland
Anaemia, unspecified
4.2
10.0
32
95
ZXD05
NOMESCO Finland
Urgent procedure
3.4
9.9
55
238
C01DA14
ATC
isosorbide mononitrate; oral
3.7
9.9
42
153
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
9.7
34
108
L04AA06
ATC
mycophenolic acid; systemic
33.0
9.6
12
*
C07AB07
ATC
bisoprolol; oral
3.7
9.5
87
506
N19
ICD-10 Finland
Unspecified kidney failure
8.0
9.4
21
31
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.2
9.3
21
47
207
Kela drug reimbursment
Chronic arrhythmias
3.6
9.1
39
142
SPAT1229
SPAT
Assessment of need for aid
5.3
9.0
20
44
N02AA05
ATC
oxycodone; systemic
3.4
9.0
45
181
R50.9
ICD-10 Finland
Fever, unspecified
3.8
8.9
34
114
C09AA02
ATC
enalapril; systemic
3.4
8.9
44
175
Z49.1
ICD-10 Finland
Extracorporeal dialysis
30.0
8.6
11
*
A28
ICPC
Limited function/disability NOS
3.4
8.6
42
165
M01AB01
ATC
indometacin; systemic, rectal
4.6
8.6
23
59
R06.0
ICD-10 Finland
Dyspnoea
3.2
8.6
54
248
I12.0
ICD-10 Finland
Hypertensive renal disease with renal failure
96.6
8.5
9
*
J01MA12
ATC
levofloxacin; systemic
3.4
8.5
40
154
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
8.5
29
90
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
8.4
8
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.1
8.4
57
272
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.4
8.4
24
65
B01AF02
ATC
apixaban; oral
3.8
8.3
31
102
A12AA04
ATC
calcium carbonate; oral
24.0
8.2
11
5
L28
ICPC
Limited function/disability (L)
3.3
7.9
40
160
JN3AD
NOMESCO Finland
Abdominal CT examination
3.8
7.9
28
89
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
7.9
44
187
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
48.2
7.8
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.2
7.8
41
168
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.6
7.7
20
50
AA1AD
NOMESCO Finland
CT of head and brain
2.9
7.6
54
262
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.6
7.6
29
97
N02AX02
ATC
tramadol; systemic, rectal
2.9
7.5
69
383
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
3.0
7.5
48
219
J01FF01
ATC
clindamycin; systemic
3.0
7.5
46
205
B05DA
ATC
Isotonic solutions
85.2
7.5
8
*
137
Kela drug reimbursment
Uraemia requiring dialysis
85.2
7.5
8
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.7
7.5
28
92
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
17.1
7.4
11
7
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
4.4
7.3
20
52
V03AE01
ATC
polystyrene sulfonate; oral
21.6
7.3
10
5
A10AE04
ATC
insulin glargine; parenteral
3.8
7.2
25
78
A10AB05
ATC
insulin aspart; parenteral
4.2
7.1
21
58
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.9
7.0
48
226
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
6.9
56
288
127
Kela drug reimbursment
Transplant complication
42.5
6.8
8
*
AN1
HP
Coronary angiography
3.5
6.8
27
92
Z49.0
ICD-10 Finland
Preparatory care for dialysis
24.1
6.8
9
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
24.1
6.8
9
*
J01DB01
ATC
cefalexin; oral
4.6
6.8
107
786
R10.1
ICD-10 Finland
Pain localized to upper abdomen
3.2
6.7
33
129
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.5
6.6
26
88
A06AD11
ATC
lactulose; oral
3.2
6.5
31
118
R11
ICD-10 Finland
Nausea and vomiting
4.2
6.5
19
52
B05DB
ATC
Hypertonic solutions
73.6
6.5
7
*
AN2
HP
Balloon angioplasty, including several vessels
10.1
6.5
12
13
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.8
6.5
46
220
H02AB04
ATC
methylprednisolone; systemic
3.3
6.4
28
101
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
4.4
6.4
17
43
N03AX12
ATC
[U] gabapentin; oral
3.1
6.4
31
120
XF400
NOMESCO Finland
ECG with 12 standard connections
3.0
6.3
34
139
201
Kela drug reimbursment
Chronic cardiac insufficiency
3.9
6.3
20
58
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.8
6.3
17
33
N03.9
ICD-10 Finland
Chronic nephritic syndrome, unspecified
+∞
6.3
6
*
M10.3
ICD-10 Finland
Gout due to impairment of renal function
+∞
6.3
6
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
6.3
6
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.8
6.2
43
202
K90
ICPC
Stroke/cerebrovascular accident
8.8
6.0
12
15
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Proper column names.
- Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV not working.
- No filters and sorters.
- Limited amount of endpoints with TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
83
254
8.50
29.40
6.4
3.2
442.72
356.34
umol/l
6.15
76
214
54
193
4.29
13.62
4.1
3.0
0.81
0.81
mmol/l
0.02
47
184
66
276
4.12
13.30
3.5
2.1
3.94
3.13
mg/l
0.53
61
232
85
433
4.37
12.72
6.2
2.8
191.73
143.44
ug/l
0.94
80
394
30
71
5.31
12.61
9.0
4.5
24.68
24.37
mmol/l
0.13
30
71
39
120
4.35
11.83
8.0
4.3
2.32
1.73
mmol/l
0.27
34
101
52
197
3.91
11.81
2.9
2.1
—
—
—
0
0
92
523
4.35
11.15
20.3
7.3
1.20
1.21
mmol/l
0.36
85
445
30
79
4.74
11.03
2.2
1.4
—
—
—
0
0
20
23
10.21
10.28
1.5
1.4
—
—
—
0
0
84
473
3.64
9.78
17.7
6.8
1.20
1.21
mmol/l
0.51
77
431
27
74
4.43
9.36
3.1
1.9
—
—
—
0
0
31
97
3.97
8.99
4.5
2.6
64.62
66.74
g/l
0.79
31
91
81
464
3.34
8.80
3.0
2.1
87.15
93.07
pmol/l
0.45
54
239
53
244
3.11
8.32
3.9
2.6
—
—
—
0
0
91
571
3.52
8.26
13.8
11.0
4.81
4.44
e9/l
0.71
81
495
38
144
3.41
8.24
1.3
1.3
33.31
10.56
u/ml
—
10
57
38
149
3.28
7.75
2.8
1.9
—
—
—
0
0
16
21
8.62
7.68
1.4
1.3
—
—
—
0
0
17
39
4.92
7.23
2.4
1.9
—
—
—
0
0
60
315
2.82
7.18
6.6
3.4
1.25
0.43
e6/l
0.57
52
239
38
160
3.02
6.78
1.4
1.3
19.06
34.22
iu/ml
—
9
49
17
42
4.56
6.61
2.9
2.2
—
—
—
0
0
18
47
4.33
6.54
5.3
1.8
0.77
0.46
g/l
0.24
18
41
35
145
3.00
6.38
14.2
7.4
4.94
5.16
kpa
0.68
35
139
35
145
3.00
6.38
14.2
7.4
11.95
11.65
kpa
0.14
35
139
11
11
10.87
6.17
4.1
5.5
14.56
11.57
mg/l
0.65
11
11
33
136
2.97
6.05
3.1
2.1
—
—
—
0
0
17
35
5.49
6.03
1.7
1.1
—
—
—
0
0
17
35
5.49
6.03
5.5
3.5
2.30
1.86
index
—
10
21
61
350
2.52
5.78
7.8
4.0
21.97
11.39
mg/mmol
0.83
50
219
74
465
2.56
5.77
5.3
2.8
—
—
estimate
—
0
0
16
42
4.25
5.75
5.3
1.8
0.00
0.00
g/l
-0.00
16
35
23
79
3.37
5.68
17.8
8.6
23.68
24.76
mmol/l
0.67
23
79
27
105
3.03
5.44
16.1
9.0
1.48
1.29
mmol/l
0.54
27
105
16
35
5.11
5.42
5.3
1.9
0.00
0.00
g/l
-0.00
16
35
37
175
2.62
5.16
3.7
1.9
31.38
29.31
s
0.73
37
169
37
177
2.58
5.03
6.4
3.3
0.80
1.53
e6/l
0.53
18
96
13
26
5.48
4.79
1.6
1.2
—
—
—
0
0
12
22
5.94
4.74
1.3
1.4
—
—
—
0
0
12
22
5.94
4.74
2.2
1.5
—
—
—
0
0
12
22
5.94
4.74
1.3
1.4
—
—
—
0
0
13
27
5.27
4.66
1.3
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
38
4.36
4.49
3.3
2.2
0.28
0.28
iu/ml
—
7
19
13
29
4.90
4.40
2.4
1.2
—
—
—
0
0
37
189
2.39
4.31
5.9
3.1
1.23
0.92
e6/l
0.15
18
107
14
42
3.64
4.19
6.9
3.3
56.64
45.44
mg/l
0.40
14
37
14
42
3.64
4.19
6.9
3.3
36.84
33.96
mg/l
0.12
14
37
14
37
4.15
4.05
6.3
3.1
3.60
1.30
ratio
—
8
18
42
239
2.17
3.73
2.4
1.7
1.48
1.70
mg/l
0.24
36
187
20
83
2.69
3.53
6.9
3.7
36.18
58.83
ml/min/173m2
2.28
11
40
11
28
4.22
3.39
1.6
1.6
—
—
—
0
0
16
64
2.73
3.02
1.4
1.5
—
—
—
0
0
10
27
3.95
2.96
1.3
1.8
0.25
0.22
g/l
—
10
27
10
27
3.95
2.96
1.3
1.8
1.24
1.12
g/l
—
10
27
19
85
2.47
2.89
1.7
1.9
1.84
1.73
%
0.12
19
69
5
6
8.63
2.77
2.2
2.5
—
—
—
0
0
5
6
8.63
2.77
4.4
2.7
—
—
—
0
0
5
6
8.63
2.77
2.2
2.5
—
—
—
0
0
5
6
8.63
2.77
2.2
2.5
—
—
—
0
0
5
6
8.63
2.77
2.2
2.5
—
—
—
0
0
22
108
2.27
2.73
3.8
3.9
—
—
—
0
0
6
10
6.25
2.73
3.8
1.7
—
—
—
0
0
11
36
3.26
2.64
1.1
1.0
—
—
—
0
0
19
92
2.27
2.43
2.2
2.3
369.79
396.02
nmol/l
0.16
19
84
70
531
1.77
2.38
5.5
4.3
0.00
0.00
estimate
-0.00
13
123
6
13
4.80
2.30
1.0
1.2
99.33
105.69
pmol/l
—
6
13
7
19
3.85
2.18
1.4
1.1
—
—
—
0
0
6
14
4.45
2.18
1.5
1.4
—
—
—
0
0
70
540
1.72
2.17
6.1
4.3
0.00
0.04
estimate
0.50
12
113
16
76
2.28
2.14
4.0
3.3
117.50
128.58
g/l
1.30
16
71
12
51
2.50
2.02
3.1
2.9
1.66
1.37
%
0.61
12
46
66
512
1.65
1.92
4.0
2.6
—
—
—
0
0
7
23
3.17
1.83
1.7
2.3
—
—
—
0
0
11
48
2.42
1.76
3.2
2.0
2.55
6.46
ug/l
0.28
11
41
5
13
3.96
1.73
1.6
1.5
—
—
—
0
0
67
533
1.59
1.68
6.1
4.3
0.00
0.00
estimate
-0.00
12
126
96
836
1.77
1.65
5.7
5.0
2.06
1.98
mu/l
0.26
90
738
5
14
3.68
1.63
1.6
1.1
—
—
—
0
0
5
14
3.68
1.63
1.6
1.4
—
—
—
0
0
5
14
3.68
1.63
1.6
1.4
—
—
—
0
0
5
15
3.43
1.54
2.2
2.1
—
—
—
0
0
5
15
3.43
1.54
1.6
1.4
—
—
—
0
0
5
15
3.43
1.54
1.6
1.4
—
—
—
0
0
5
15
3.43
1.54
2.2
2.1
—
—
—
0
0
5
15
3.43
1.54
2.2
2.1
—
—
—
0
0
6
21
2.95
1.52
1.5
2.2
—
—
—
0
0
9
37
2.55
1.51
1.9
1.8
—
—
—
0
0
9
38
2.48
1.49
1.9
1.8
—
—
—
0
0
6
22
2.82
1.45
1.3
2.0
—
—
—
0
0
57
451
1.51
1.38
9.2
4.6
42.52
43.87
ng/l
0.05
48
352
22
324
0.61
1.29
2.7
3.5
0.74
0.79
ug/l
0.12
17
220
10
49
2.14
1.26
2.4
2.7
—
—
—
0
0
7
30
2.41
1.14
1.6
1.9
—
—
—
0
0
33
417
0.71
0.87
3.7
4.7
23.43
22.06
%
0.13
11
215
97
893
1.47
0.84
6.9
5.4
6.35
6.11
mmol/l
0.83
92
803
9
55
1.69
0.75
1.4
1.9
—
—
—
0
0
7
38
1.89
0.75
1.1
1.4
—
—
—
0
0
5
25
2.04
0.73
2.0
1.7
—
—
—
0
0
5
26
1.96
0.71
1.2
1.2
—
—
—
0
0
5
26
1.96
0.71
1.8
2.0
—
—
—
0
0
5
26
1.96
0.71
1.2
1.2
—
—
—
0
0
7
43
1.67
0.68
1.9
1.4
—
—
—
0
0
6
35
1.75
0.58
1.0
1.3
—
—
—
0
0
97
920
1.29
0.46
6.9
6.1
2.17
2.57
mmol/l
4.97
97
837
6
94
0.62
0.44
1.3
1.4
—
—
—
0
0
92
870
1.25
0.42
5.5
4.5
1.60
1.28
mmol/l
2.41
92
785
32
364
0.83
0.33
2.8
2.0
1.49
1.33
mmol/l
0.54
32
289
48
525
0.86
0.31
4.5
5.9
1.43
3.12
ug/l
1.36
42
464
9
116
0.76
0.29
7.8
8.7
—
—
—
0
0
8
65
1.25
0.28
1.5
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
175.83
—
0
13
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
38
407
0.90
0.16
6.4
4.4
0.00
0.00
estimate
—
10
106
33
314
1.07
0.08
5.1
4.4
0.00
0.00
estimate
—
10
113
8
75
1.07
0.07
1.5
1.5
—
—
—
0
0
10
109
0.91
0.04
1.8
1.3
—
—
—
0
0
29
299
0.96
0.03
6.2
3.9
0.00
0.00
estimate
—
9
98
0
5
0.00
0.00
0.0
1.0
—
1680.00
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint GOUT_SCND and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| GOUT_SCND | 2.432 [1.7, 3.49] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.198 |
During the follow-up period (1.1.1998 — 31.12.2019), 157 out of 306 females with GOUT_SCND died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| GOUT_SCND | 3.031 [2.18, 4.21] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 239 out of 515 males with GOUT_SCND died.
Mortality risk
Mortality risk for people of age
years, who have GOUT_SCND.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.272% | 0.647% |
| 5 | 1.404% | 3.526% |
| 10 | 3.392% | 7.938% |
| 15 | 6.578% | 14.883% |
| 20 | 11.242% | 24.572% |
Relationships between endpoints
↥Index endpoint: GOUT_SCND – Other secondary gout
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data